Curtana Pharmaceuticals is a privately-held, preclinical-stage biopharmaceutical company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma (GBM) and other brain cancers.